Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Taking the Long VIEW in AMD

Lloyd Clark, MD

Since the completion of two parallel phase 3 randomized, double-masked, multicenter clinical trials, VIEW 1 and VIEW 2, long-term outcomes of aflibercept (Eylea, Regeneron) have been assessed in further clinical trials. In this installment of the AMD Resource Center, W. Lloyd Clark, MD, summarizes some of the results of an extension study that included patients from the VIEW 1 trial, which accumulated data out to 4 years of follow-up, and the 1-year interim results of a further 2-year treat-and-extend follow-up study called RANGE

Since the completion of two parallel phase 3 randomized, double-masked, multicenter clinical trials, VIEW 1 and VIEW 2, long-term outcomes of aflibercept (Eylea, Regeneron) have been assessed in further clinical trials. In this installment of the AMD Resource Center, W. Lloyd Clark, MD, summarizes some of the results of an extension study that included patients from the VIEW 1 trial, which accumulated data out to 4 years of follow-up, and the 1-year interim results of a further 2-year treat-and-extend follow-up study called RANGE

We use cookies to offer a better user experience and to analyze site traffic. To comply with the European General Data Protection Regulation (GDPR), we are implementing a cookie consent manager to provide residents of the EU/EEA with the ability to customize their cookies. Until this is available, your continued use of this site will be deemed as consent to use of cookies.